A single product candidate that provides clinical benefit across multiple indications and patient populations allows more conditions to be treated quicker, resulting in more efficient research and development for sponsors. However, developing these types of products is not without its challenges. Sponsors that strategically plan for Investigational New Drug (IND) management can maximize limited resources, simplify activities surrounding IND maintenance, and ensure IND holders comply with required responsibilities.
In this white paper, you will learn:
- Benefits of consolidating general information into one place and aligning dates to streamline reporting
- Pediatric requirements to consider early in the development process
- Possible labeling scenarios and requirements
- Opportunities for accelerating development and eventual approval
You may also be interested in:
White Paper
Regulatory Considerations for Biotech
Innovative biotech products present a complex regulatory environment. For this reason, a formidable regulatory strategist is a critical member of the…
Page
Global Regulatory Affairs
PRA’s Global Regulatory Affairs (GRA) group brings more than 20 years’ experience navigating the complex regulatory environment. We leverage our…
White Paper
Pediatric Product Development Plan
Development of the Pediatric Study Plan (PSP) for the United States Food and Drug Administration and the Pediatric Investigation Plan (PIP) for the…